Abstract
Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 1987-1993 |
| Number of pages | 7 |
| Journal | Clinical Ophthalmology |
| Volume | 7 |
| DOIs | |
| State | Published - Oct 9 2013 |
Fingerprint
Keywords
- Age related macular degeneration
- ARMS2
- Bevacizumab
- Complement factor H (CFH)
- LOC387715
- Ranibizumab
- Single nucleotide polymorphisms
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Ophthalmology
Cite this
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. / Kitchens, John W.; Kassem, Nawal; Wood, William; Stone, Thomas W.; Isernhagen, Rick; Wood, Edward; Hancock, Brad A.; Radovich, Milan; Waymire, Josh; Li, Lang; Schneider, Bryan.
In: Clinical Ophthalmology, Vol. 7, 09.10.2013, p. 1987-1993.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
AU - Kitchens, John W.
AU - Kassem, Nawal
AU - Wood, William
AU - Stone, Thomas W.
AU - Isernhagen, Rick
AU - Wood, Edward
AU - Hancock, Brad A.
AU - Radovich, Milan
AU - Waymire, Josh
AU - Li, Lang
AU - Schneider, Bryan
PY - 2013/10/9
Y1 - 2013/10/9
N2 - Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.
AB - Purpose: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). Methods: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. Results: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. Conclusion: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.
KW - Age related macular degeneration
KW - ARMS2
KW - Bevacizumab
KW - Complement factor H (CFH)
KW - LOC387715
KW - Ranibizumab
KW - Single nucleotide polymorphisms
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84885448955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885448955&partnerID=8YFLogxK
U2 - 10.2147/OPTH.S39635
DO - 10.2147/OPTH.S39635
M3 - Article
C2 - 24143065
AN - SCOPUS:84885448955
VL - 7
SP - 1987
EP - 1993
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
SN - 1177-5467
ER -